<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248754</url>
  </required_header>
  <id_info>
    <org_study_id>H10-02888</org_study_id>
    <nct_id>NCT01248754</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study</brief_title>
  <official_title>A Phase II Study Using 18F-FDOPA Positron Emission Tomography Imaging for Neurosurgery and Assessment of Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alan Nichol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 18F-FDOPA PET tracer is an amino acid analogue that can be used to visualize high-grade
      glioma not clearly identified on diagnostic MRI. Use of 18F-FDOPA PET will permit
      neurosurgeons to achieve a complete resection more frequently.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects that have a complete resection of the volume of 18F-FDOPA PET tracer on their postoperative 18F-FDOPA PET scan.</measure>
    <time_frame>Less than 72 hours postoperatively</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cancer (High-grace Glioma)</condition>
  <arm_group>
    <arm_group_label>18F-DOPA PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical neuronavigation with 18F-DOPA PET imaging</intervention_name>
    <description>Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.</description>
    <arm_group_label>18F-DOPA PET imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Contrast-enhancing mass on diagnostic brain CT or MRI strongly suggesting a diagnosis
             of WHO grade III or IV glioma

          -  Karnofsky Performance status (KPS) ≥ 70

          -  Age ≥18 years

          -  Subject is able to understand and consent to study

          -  Glomerular filtration rate (GFR) ≥ 45 ml/minute

        Exclusion Criteria:

          -  Indication for urgent craniotomy to relieve mass effect

          -  Only stereotactic biopsy indicated because tumour is located in eloquent brain.

          -  The enhancement on the T1 MRI sequence involves or abuts the basal ganglia

          -  Previous intracranial malignancy or any invasive malignancy unless free of disease &gt; 5
             years

          -  Prior cranial irradiation

          -  Contra-indications to systemic radiation exposure: pregnancy or breast feeding

          -  Subject exceeds the weight limit of the PET scanner bed (204.5 kg)

          -  Subjects taking medication such as Levodopa for the treatment of Parkinson's Disease

          -  Allergies or other contraindication to CT contrast or MRI contrast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Nichol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lions Gate Hospital</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.bccancer.bc.ca</url>
    <description>BC Cancer Agency</description>
  </link>
  <link>
    <url>http://www.surgery.ubc.ca/</url>
    <description>UBC Department of Surgery</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>British Columbia Cancer Agency</investigator_affiliation>
    <investigator_full_name>Alan Nichol</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>Neurosurgery</keyword>
  <keyword>Neuronavigation</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>FDOPA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroxyphenylalanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

